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Theinnateimmunesystemistheﬁrstlineofdefenceinresponsetopathogeninfection.Naturalkiller(NK)cellsperformavitalrole
in this response with the ability to directly kill infected cells, produce cytokines, and cross-talk with the adaptive immune system.
These eﬀector functions are dependent on activation of NK cells which is determined by surface receptor interactions with ligands
on target cells. Of these receptors, the polymorphic killer immunoglobulin-like receptors (KIRs), which interact with MHC class
1 (also highly polymorphic), are largely inhibitory, and exhibit substantial genetic diversity. The result is a signiﬁcant variation
of NK cell repertoire between individuals and also between populations, with a multitude of possible KIR:HLA combinations.
As each KIR:ligand interaction may have diﬀerential eﬀects on NK cell activation and inhibition, this diversity has important
potentialinﬂuencesonthehostresponsetoinfections.GeneticstudieshavedemonstratedassociationsbetweenspeciﬁcKIR:ligand
combinations and the outcome of viral (and other) infections, in particular hepatitis C and HIV infection. Detailed functional
studies are not required to deﬁne the mechanisms underpinning these disease associations.
1.Introduction
Natural Killer (NK) cells are key eﬀector cells of the innate
immune system, and as such are crucial in the antiviral
immune response. They are multifunctional, with an ability
to interact directly with infectious agents, through pattern
recognition receptors, with infected cells, via expressed cell
surface receptors, and with cells of the adaptive immune
system via cell-cell interactions and through secretion
of cytokines [1]. Such cytokines are predominantly pro-
inﬂammatory such as interferon (IFN)-γ or tissue growth
factor(TGF)-β,butmayinsomecasesbeimmunoregulatory
[2].
NK cell activation is controlled by a complex balance
between activating and inhibitory receptors such that the
net signal derived from these receptors is integrated to
determine whether or not NK cell eﬀector functions are
initiated [3–5]. Many of these receptors are monomorphic
and expressed on all cells. Furthermore, they are relatively
well conserved between human and mice. This particularly
applies to the activating receptors, including NKp46 and
NKG2D, which have been shown to be especially important
in the host-pathogen interaction. The inhibitory receptors,
however, fall into two main, although not exclusive, groups:
the killer-cell immunoglobulin-like receptors (KIRs) and the
NKG2 families. Both have major histocompatibility complex
(MHC) class I ligands, but of diﬀerent types. The NKG2
family, of which NKG2A is the main inhibitory member,
is relatively nonpolymorphic and conserved throughout
evolution. The functional receptor, a heterodimer of CD94
and NKG2A, binds human leucocyte antigen (HLA)-E plus
signal peptides derived from classical HLA class I alleles
[6]. Conversely, the KIRs are diverse and polymorphic,
with polymorphic HLA class I ligands. Thus, whilst both
families may be important in the immune response against
pathogens, the KIR family are more likely to be responsible
for generating diversity in the immune response to speciﬁc
pathogens within the human population. They have received
much attention as potential disease association markers for a
number of infections which have discrete clinical outcomes.
Theaimofthispaperistosummarizeourcurrentknowledge
of how KIRs and KIR ligand diversity may inﬂuence the
outcome of a number of key human infections.2 Journal of Biomedicine and Biotechnology
2. StructureandGenetics
KIRs exhibit substantial diversity at both the allelic and
haplotypic levels. Furthermore, their expression on NK cells
is stochastic and variegated [7, 8]. The result is a diverse
repertoire of NK cell clones within an individual and also
substantial NK cell diversity between populations. Addition-
ally, their HLA class I ligands are extremely polymorphic and
this generates a further level of functional diversity. These
factors likely synergize to generate varying susceptibility to
pathogens and disease.
KIRs are encoded in a 150kb region on chromosome
19q13.4 within the leukocyte receptor complex (LRC) [9].
There are at least 17 KIR genes or pseudogenes with
substantial allelic diversity of many of these genes [10,
11]. Comparison of humans and nonhuman primates has
revealedtherapidevolutionofthislocus,mostlikelythrough
a combination of gene duplication and nonhomologous
recombination [12]. This evolution is thought to be driven
by selective pressure from exposure to pathogens, and also
by the pressure for reproductive success [13]. The sum total
of these eﬀects is substantial genetic diversity at the level
of the locus, which has been simpliﬁed into two main KIR
haplotypes: “A” and “B” based on gene content. The B
group of haplotypes are deﬁned by the presence of one or
more of the following genes: KIR2DL5, KIR2DS1, KIR2DS2,
KIR2DS3, KIR2DS5, and KIR3DS1. Conversely, the group A
haplotypes are deﬁned by the absence of all of these genes
and the presence of KIR2DS4 [14]. The two haplotypes
are thought to have been maintained within the human
population by balancing selection; however, the frequency
of these haplotypes varies substantially between populations
[15, 16]. In general, A haplotypes are associated with an
improved response to pathogens, whereas B haplotypes are
associated with improved reproductive ﬁtness [17–19].
The KIR proteins are members of the immunoglobulin
(Ig) superfamily of receptors. Their nomenclature is based
on their structure, where the number of Ig-like extracellular
domains (2D or 3D) and the length of the cytoplasmic tail
(long, L or short, S) deﬁnes the name of the protein. The
long cytoplasmic tails contain immunoreceptor tyrosine-
based inhibitory motifs (ITIMs) and confer an inhibitory
signal when the receptors are engaged with their ligands. The
short tailed receptors lack ITIMs and are activating. These
activating receptors have a transmembrane lysine residue
which allows binding to the immunoreceptor tyrosine-based
activating motif (ITAM) containing adaptor DAP12. Thus,
KIR2DL1 has two extracellular Ig-like domains, a long
intracytoplasmic tail and transduces an inhibitory signal,
whereas KIR3DS1 has three extracellular Ig-like domains
and a short intracytoplasmic tail and associates with DAP12
to transduce an activating signal. An exception to this
is KIR2DL4 which has a long intracytoplasmic tail, but
associates with FcεR1γ to transduce an activating signal [20].
Thereisalsodiversityintheconﬁgurationoftheextracellular
domains, as for the two Ig domain KIRs the extracellular
domains may be in a D1D2 (the majority) or D0D2
(KIR2DL4 and KIR2DL5) conﬁguration. This extracellular
domain organisation reﬂects evolutionary relationships, and
thustheD0D22IgdomainKIRscomprisetheLineageIKIRs,
the 3 IG domain KIRs excluding KIR3DL3 form the Lineage
II KIRs and the D1D2 2Ig domain KIRs form Lineage III
[21]. Lineage I is the most conserved of the lineages having
representative members in the old world monkeys, whereas
the Lineage III KIRs are not well conserved even between
humans and the common chimpanzees.
3.KIR Ligands
That inhibitory KIRs interact with polymorphic HLA class
1 ligands is well established, and in general the Lineage
III KIRs bind MHC-C. Thus, the inhibitory receptors
KIR2DL1,2DL2,and2DL3arespeciﬁcforHLA-C:KIR2DL1
binds alleles of HLA-C with lysine at position 80 (HLA-
C2), whereas KIR2DL2 and 2DL3 bind HLA-C alleles with
asparagine at position 80 (HLA-C1) [22, 23]. The aﬃnity
of these interactions may diﬀer [24], and it is thought
that KIR2DL3:HLA-C1 is a relatively weak interaction,
whilst KIR2DL2:HLA-C1 and KIR2DL1:HLA-C2 are rel-
atively stronger [25]. Of the Lineage II KIRs, KIR3DL1
recognises HLA-B alleles with the Bw4 serological motif
(HLA-Bw4) and also some HLA-A alleles also with the Bw4
motif; KIR3DL2 binds HLA-A3 and -A11 [26, 27]. The
speciﬁc recognition of HLA class 1 by the activating KIRs
is less well deﬁned (Table 1), although sequence homology
predicts they should have similar binding speciﬁcities as
their inhibitory counterparts. Thus, binding of KIR2DS1
to HLA-C is of a similar speciﬁcity to that of KIR2DL1,
but at a substantially lower aﬃnity [28]. Furthermore,
although KIR2DS2 and KIR3DS1 share substantial sequence
homology with their inhibitory counterparts, KIR2DL2/3
and KIR3DL1, respectively, binding to the relevant ligands
has not been convincingly established. One mitigating factor
is that all the inhibitory KIRs tested to date have been shown
to have selectivity for the peptide bound by MHC class I, and
this implies that speciﬁc peptides, either host or viral, may
modulatebindingofKIRstotheirMHCclassIligands.Thus,
the absence of a deﬁned HLA speciﬁcity may be because key
(host or viral) peptides that determine the interaction have
yet to be tested, or that they genuinely do lack a ligand [29].
As the gene cluster for HLA class I is located on chromo-
some 6, inheritance is unlinked to KIRs on chromosome 19.
Thisgeneratesdiversityinthenumberofpotentialinhibitory
interactions that the NK cells from a single individual may
have. For instance, an individual with both group 1 and
group 2 HLA-C alleles and also an HLA-Bw4 allele has
the potential for three inhibitory KIR:HLA interactions,
whereas an individual homozygous at the HLA-C locus and
with no HLA-Bw4 alleles has only one inhibitory KIR:HLA
interaction. Thus, in genetic studies it may be necessary
to incorporate the KIR ligand interactions into a biological
model, rather than just considering KIRs in isolation.
Within an individual, the KIRs, in combination with
the CD94:NKG2A heterodimer, are expressed in a variegated
pattern on NK cells. This generates an NK cell repertoire
based on inhibitory receptors for self-MHC class I. The pat-
terns of expression are complex, but have recently been seg-
regated into ﬁve main types [8]. The relevance of an NK cellJournal of Biomedicine and Biotechnology 3
Table 1: KIRs molecules and their HLA ligands.
KIRs Ligand
2DL1 HLA-C2
2DS1 HLA-C2
2DL2 HLA-C1
2DL3 HLA-C1
2DS2 HLA-C1
2DL4 HLA-G
2DL5 Unknown
2DS3 Unknown
2DS4 HLA-A11, HLA-C
2DS5 Unknown
3DL1 HLA-Bw4
3DS1 HLA-Bw480I
3DL2 HLA-A3,11
3DL3 Unknown
repertoire may be similar to that of a T-cell repertoire. Thus,
if a speciﬁc receptor:ligand combination is important for
recognizing a host cell infected by a speciﬁc virus, then indi-
viduals who have a repertoire with more NK cells expressing
that speciﬁc receptor may have a better immune response
to that speciﬁc infection. Furthermore, NK cells that do not
e x p r e s sar e c e p t o rf o rs e l f - M H Cc l a s sIa p p e a rt ob er e l a t i v e l y
hypofunctional, which implies that they are likely to be less
responsive to pathogens [30]. This is thought to be the result
of selection and “licensing” processes that are dependent on
these receptors during NK cell maturation [31, 32].
Thus, diversity within the KIR system is present at the
level of the locus, of the allele, of the ligand, and within
their expression patterns. It may be that all these factors can
inﬂuence the host immune response to infection. We will
now focus on how this diversity may impact the outcome
some key human infections.
4.HepatitisCVirus(HCV)
Infection with HCV leads to chronicity in the majority of
cases. These individuals remain anti-HCV antibody positive
with detectable HCV RNA, as compared to those who clear
infection who remain antibody positive long after exposure,
but have no detectable HCV RNA. Those with chronic
infection have long-term sequelae that include cirrhosis
and hepatocellular cancer (HCC). NK cells provide an
early line of defence in the host response to HCV [33–
35]. Furthermore, functional studies have demonstrated NK
cell abnormalities in chronic infection, including decreased
levels in the peripheral blood [36] and reduced cytotoxicity
[37, 38]. This function can normalise with interferon-
based treatment [39], and in patients where cytotoxicity is
preserved, progression of liver ﬁbrosis is reduced [36].
The categorization of HCV exposed individuals into
those with and without detectable HCV RNA provides a
simple variable which can be used to elicit genetic factors
associated with protection against HCV. In a study of
1037 exposed individuals the compound KIR:HLA genotype
KIR2DL3anditsligandthegroup1HLA-C(HLA-C1)alleles
was associated with resolution of infection. This was in a
recessive model in which protection was found in those
homozygous for both KIR2DL3 and HLA-C1, and then only
in individuals exposed with relatively low inocula such as
via intravenous drug use (IVDU) as compared to those
exposed through infected blood products [40]. This ﬁnding
was conﬁrmed in a subsequent study of 160 individuals
with IVDU as the risk factor for infection [41]. The ﬁnding
that inhibitory interactions are protective against a viral
infection initially seems counterintuitive. However, natural
killer cells are held in check by their inhibitory receptors
and, as originally proposed by the missing-self hypothesis,
loss of these interactions is a key mechanism to permit
NK cell activation [4]. KIR2DL3:HLA-C1 is a lower avidity
interactionthanKIR2DL2:HLA-C1andalsoKIR2DL1:HLA-
C2, and therefore the observed correlation with outcome of
HCV infection is consistent with the binding data in that
lower avidity interactions are more easily overcome than
higher avidity ones [24,25].Although,HCV does not appear
to substantially aﬀect MHC class I expression, it has recently
been found that NK cells are unexpectedly responsive to
changes in the peptide repertoire of MHC class I through
a mechanism of peptide antagonism. Therefore, it may be
that this mechanism is more important in perturbing the
KIR2DL3:HLA-C1 interaction than wholesale downregula-
tion of MHC class I [42]. Functional data in inﬂuenza
infection support this inhibitory receptor hierarchy. In vitro
studies demonstrate that NK cells from individuals with
the genotype KIR2DL3:HLA-C1 were activated more rapidly
by autologous inﬂuenza infected targets than those from
individuals with a KIR2DL1:HLA-C2 genotype [43]. The
protective eﬀects of KIR2DL3:HLA-C1 homozygosity have
also been demonstrated for individuals who are exposed to
HCVinfectionthroughhigh-riskbehaviour,anddonothave
antibodies to HCV, or HCV RNA [44]. Furthermore, as KIRs
are expressed on NK cells in a variegated manner, homozy-
gosity may be protective because individuals with two copies
of this gene have more NK cells expressing the protective
KIRs. Indeed individuals that resolve HCV infection do have
a higher frequency of NK cells expressing HLA-C-speciﬁc
KIRs [33]. Additionally, individuals successfully treated with
interferon-α-based regimens also have a higher frequency of
KIR2DL3:HLA-C1, than those who do not make successful
treatment responses [44, 45]. Thus, this gene combination
has a consistently protective eﬀect across several diﬀerent
scenarios within HCV exposure and infection. Recently, this
protection has been mapped to the allelic level and it has
been shown that HLA-Cw∗07 (one of the KIR2DL3 ligands)
was not protective against chronic infection, nor associated
with a successful treatment response. This may be related
to the education of NK cells from these individuals, as
this allele has been shown to be associated with a “strong
educator” phenotype, that is, NK cells from these individuals
produce relatively large amounts of IFNγ compared to
individuals with other HLA types [8]. Finally, HLA-C1 and
also KIR3DS1 were found to be independently protective
against the development of hepatocellular carcinoma in
individuals with chronic HCV infection [46].4 Journal of Biomedicine and Biotechnology
However, this simple model of genetic protection has not
been found in all patient populations. KIR2DL3 is found
on the “A” group of haplotypes, as is KIR2DS4. Consistent
with this, KIR2DS4 has been associated with protection
against chronic HCV infection [47]. Similarly, the B group
of haplotypes are marked with KIR2DL5, and have been
found to be associated with a poor response to treatment for
HCV [48]. Finally, KIR2DL3:HLA-C1 was not found to be
protective in a cohort of HIV/HCV coinfected individuals,
implying that the presence of HIV infection modulates the
protective eﬀect of KIRs [49].
Due to the diﬃculty of obtaining samples in the acute
phase of HCV infection, individuals have been studied
predominantly in the chronic phase. Thus, it has been
diﬃcult to correlate these genetic eﬀects with function.
Furthermore, in the acute phase of infection, there are
generally lower numbers of CD56dim NK cells which are the
KIR expressing subpopulation, suggesting sequestration of
these cells to the liver [33, 34]. Indeed, lower frequencies
of peripheral blood NK cells expressing the key activating
receptors NKp30, NKp46, and NKG2D are found in the
acute phase of HCV infection in those that resolve infection
compared to those that become chronically infected [33].
During chronic infection with HCV multiple changes in NK
cell receptor expression have been observed, but in general
KIR expression is low or normal, and NKG2A expression is
increased [50–52]. One correlate is that CD107a expression
on peripheral NK cells is increased on KIR2DL2/3+ NK cells
inacuteHCVinfectioncomparedtoKIR2DL1+NKcellsand
also compared to KIR2DL2/3+ NK cells from healthy donors
[34].
5.HepatitisBVirus(HBV)
Like HCV, HBV is a hepatotrophic virus that causes a major
global health problem. An estimated 2 billion individuals
have been infected with HBV and approximately 350 million
aresuﬀeringfromchronicdisease[53].Ofthosewithchronic
infection 25% die of the complications of HCC or cirrhosis,
resulting in 600,000 deaths per year. NK cells are activated
in the early response to infection, and there is substantial
population variability in the rates of HBV infection [54].
Whilst detailed genetic and functional analyses exploring
KIR-HLA inﬂuences on HBV in large cohorts of HBV are
lacking, Lu et al. analysed the KIR genes in 150 patients with
chronic HBV infection (CHB), 251 spontaneous resolvers,
and 451 healthy controls. They found a lower frequency of
the A haplotype, and higher frequency of the B haplotype
in patients exposed to hepatitis B compared with healthy
controls, implying a susceptibility eﬀect of the B haplotype
[18]. A second study, comparing 182 CHB patients with 140
healthy controls, was consistent with this observation [55].
The authors reported that KIR2DL3:HLA-C1 homozygosity
was protective, and KIR2DL1:HLA-C2 was associated with
susceptibility to HBV infection. Thus, there are important
similarities between hepatitis C and hepatitis B infections,
despite these viruses being phylogenetically unrelated.
6.HIV
HIV was the ﬁrst viral infection for which an association
of KIRs with outcome was observed. In a seminal study
performed by Martin et al. [56], it was shown that the
activating receptor KIR3DS1 was associated with a beneﬁcial
eﬀect in HIV in combination with HLA-B alleles that have
the Bw4 serological epitope with isoleucine at position 80
(HLA-Bw480I). This epistatic interaction protected against a
decline in CD4 count, and hence the development of AIDS.
Subsequent work from the same group has also shown that
this combination delays the onset of opportunistic infection
and is associated with a slightly lower viral load [56–58].
Overall this association forms an attractive model as the
activating receptor-ligand interaction could be associated
with enhanced NK cell reactivity, and, hence, an improved
antiviral immune response. Furthermore, HIV has been
shown to selectively downregulate HLA-A and -B, but not
HLA-C, implying that it may target this speciﬁc interaction
[59]. However, to date it has been diﬃcult to demonstrate
clearly that KIR3DS1 binds HLA-Bw480I alleles in binding
assays. This is not unexpected as the avidity of activating
KIRs for MHC class I are signiﬁcantly lower than for the
inhibitory KIRs with similar predicted binding speciﬁcity
[60, 61]. Furthermore, the peptide bound by the MHC
class I molecule can profoundly inﬂuence the interaction
of KIRs with MHC class I [28, 42, 62]. This complexity
in binding may be one explanation for diﬀerences between
these and other studies, such as that of Gaudieri et al. in
which KIR3DS1 was not noted to be protective but speciﬁc
HLA-B alleles were [63]. Additionally, Boulet et al. found
a higher prevalence of KIR3DS1 in a cohort of injection
drug users that remained HIV seronegative as compared to
a matched seropositive cohort [64]. However, they found
no association with speciﬁc HLA-B alleles in this relatively
small cohort. Notwithstanding this, Alter et al. have demon-
strated signiﬁcant inhibition of viral replication in HIV-
infected HLA-Bw480I-positive T cells when cultured with
KIR3DS1+ NK cells [65]. This ﬁnding was supported in a
subsequent study demonstrating increased IFNγ production
and CD107a upregulation in HIV-infected individuals with
the KIR3DS1, but not speciﬁcally the KIR3DS1/HLA-Bw480I
compound genotype [66].
In addition to a model based on activating receptor-
ligand interactions, a hierarchy of inhibitory receptor-ligand
interactions may also be associated with outcome of HIV
infection. For the most part KIR3DL1 and KIR3DS1
segregate as alleles at a single locus. KIR3DL1 alleles are also
extremely polymorphic with more than 50 alleles described
[67]. These alleles are associated with diﬀerent levels of
expression of the KIR3DL1 allele and have been correlated
with outcome of HIV infection [68, 69]. Martin et al. found
that the high-expressing KIR3DL1 alleles combined with
HLA-B∗57 (a HLA-Bw480I allele) was the most protective
combination against progression of HIV. In this analysis,
it was more protective than KIR3DS1 in combination with
HLA-Bw480I. However, the most protective KIR allele was
KIR3DL1∗004, which is not expressed at the cell surface.
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intracellular interaction of KIR3DL1∗004 either with its
ligand, in a manner similar to the endosomal interaction of
KIR2DL4 with HLA-G, or with other NK cell receptors [70].
The protective eﬀects of high expressing KIR3DL1 alleles
and HLA-B∗57 were subsequently independently conﬁrmed
at an immunogenetic level, and functional data from this
same group has shown that KIR3DL1+ NK cells from IVDUs
with a HLA-Bw4 ligand have enhanced functionality, as
determined by CD107a expression as well as IFNγ and TNFα
secretion [64, 71].
Whilst HLA-B has been associated with the outcome
of HIV infection in a number of studies, recent genome-
wide association studies have also highlighted the relevance
of HLA-C in determining the viral set point and also in
deﬁning “elite controllers” of HIV infection [72, 73]. Whilst
HLA-C can present HIV-derived peptides to T cells [74],
this association may be related to epistatic interactions with
K I R s .T od a t el a r g es t u d i e sh a v en o td e ﬁ n e dap r o t e c t i v e
combination of speciﬁc KIRsand HLA-C allotypes, although
they have been reported to be protective against HIV-1
transmissioninarelativelysmallstudyofAfricansexworkers
[75]. Nevertheless, the absence of genetic associations does
not mean that the HLA-C speciﬁc KIRs have no role in
controlling HIV infection. If both HLA-C1 and HLA-C2
conferred similar degrees of protection against HIV, their
role would not be revealed by the broad consideration
of KIRs and HLA-C1 and HLA-C2 interactions. In depth
allelic analysis may therefore be required. The -35 C/T
polymorphism at the HLA-C locus, identiﬁed as protective
in the genome-wide association study of Fellay et al., is
associated with the level of HLA-C expression, and higher
levels of HLA-C expression have also been associated with
slower progression to AIDS and improved viral control [72,
76].ThisisreminiscentoftheeﬀectsofKIR3DL1expression,
and it may be that there are diﬀerences in NK cell education
between high and low HLA-C expressers, which are reﬂected
in their antiviral activity. Alleles of HLA-Cw∗07, which are
associated with the “strong educator” phenotype, have the
nonprotective -35 polymorphism (a “T” allele), are generally
expressedatlowlevelsandareassociatedwiththemostrapid
progression of disease [76]. Conversely, alleles expressed at
high levels tend to have the “C” allele and are associated with
slower progression. Thus, HIV illustrates the complexity of
how KIRs and MHC may interact to determine the outcome
of HIV infection, with the potential to generate multiple
models to explain the immunogenetic ﬁndings.
7. Other Infections
KIRs have been implicated most strongly in HCV and HIV
infections, which to some extent reﬂects the focus of the
immunogenetic community on these important diseases.
These pathogens cause chronic infection with readily mea-
surable outcomes which can be used to stratify individuals
into disease phenotypes. The observation that KIR genotype
isimportantfortheresponsetoinﬂuenzainvitroimpliesthat
KIRs may also be important for other viral infections and
thattheyprovideaselectiveadvantageagainstpathogensthat
may cause acute disease only.
Additionally, NK cells are thought to be particularly
relevant for viral infections of the herpes family [77]. Thus,
although CMV causes a latent infection in the majority of
infected individuals, in immunocompromised individuals it
can reactivate, and cause a life-threatening illness. In par-
ticular, it can severely compromise individuals undergoing
bone marrow transplantation (BMT). Despite substantial
variability in protocols for this procedure, a consistent
ﬁnding appears to be that having more donor activating KIR
genes helps to prevent CMV reactivation [78–80].
Activating KIRs genes are also associated with protection
against human papilloma virus (HPV) in the relatively
unusual setting of recurrent respiratory papillomatosis
(RRP), which is due to an impaired immune response to
HPV. In one study, protection was associated with KIR2DS1,
KIR2DS5, and KIR3DS1 [81]. Interestingly, KIR3DS1 is
positively associated with the development of another HPV-
associated disease, cervical neoplasia [82]. The authors
suggest that the increased activation of NK cells leads to
chronic inﬂammation and, hence, cancer. Thus, these two
studies are consistent with each other in that it appears
that an absence of KIR3DS1+ NK cells permits active
replication of HPV, whereas in cervical neoplasia the activity
of KIR3DS1+ NK cells, in the absence of viral eradication,
leads to ongoing inﬂammation.
Like CMV, herpes simplex virus (HSV) causes an asymp-
tomatic infection in the majority of individuals. However,
symptomatic infection may occur in relatively immunocom-
petent individuals. The KIR genes, KIR2DL2 and KIR2DS2,
which are in tight linkage disequilibrium, were associated
with asymptomatic HSV infection [83]. However, due to this
tight linkage, it was impossible to determine whether it was
the activating or the inhibitory receptor that was associated
with a poor response.
In addition to their role in viral infections, NK cells may
also aﬀect the response to protozoa [84], and there may
also be a role for KIRs in aﬀecting outcome. In a study of
23 individuals, those with the allele KIR3DL2∗002 secreted
higherlevelsofIFNγ inresponsetoPlasmodiumfalciparum-
infected red blood cells [85]. As red blood cells are MHC
class I deﬁcient, this may reﬂect an inﬂuence of KIR:HLA
on NK cell-macrophage cross-talk, as opposed to any direct
interaction between NK cells and infected red blood cells
[85, 86]. Alternatively, it may be an eﬀect of a gene in linkage
with KIR3DL2∗002 or related to diﬀerential education of
NK cells from individuals with this haplotype. Thus, in these
diverseinfectionsKIRgeneticshavethepotentialtoinﬂuence
outcome. Larger and more deﬁnitive studies are required.
8. Summary
Natural killer cells are important players in an eﬀective anti-
viral immune response. Their expression of multiple cell
surface receptors implies that during diﬀerent infections
diﬀerent receptors are likely to be important. Many of these
receptors are monomorphic and expressed on all NK cells.
KIRs have a variegated expression pattern, and their complex
genetics coupled with their HLA class I ligands imply that
they are involved in generating population diversity in the6 Journal of Biomedicine and Biotechnology
antiviral immune response. Tenable models based on both
activating and inhibitory receptor-ligand interactions have
been generated by detailed genetic studies involving large
cohorts. Whilst functional studies have shed some light on
these associations, the molecular mechanisms underpinning
these genetic models still requires ﬁne tuning.
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